Veena Charu

3.1k total citations · 1 hit paper
45 papers, 1.7k citations indexed

About

Veena Charu is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Veena Charu has authored 45 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 17 papers in Oncology and 10 papers in Immunology. Recurrent topics in Veena Charu's work include Erythropoietin and Anemia Treatment (20 papers), Iron Metabolism and Disorders (11 papers) and Biosimilars and Bioanalytical Methods (10 papers). Veena Charu is often cited by papers focused on Erythropoietin and Anemia Treatment (20 papers), Iron Metabolism and Disorders (11 papers) and Biosimilars and Bioanalytical Methods (10 papers). Veena Charu collaborates with scholars based in United States, Australia and United Kingdom. Veena Charu's co-authors include Alan Cartmell, Julio Hajdenberg, A. Macciocchi, Peter D. Eisenberg, Steven M. Grunberg, Dianne Tomita, David H. Henry, Allan Lipton, Fred Saad and Gary Richardson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Veena Charu

44 papers receiving 1.7k citations

Hit Papers

Superiority of denosumab to zoledronic acid for preventio... 2012 2026 2016 2021 2012 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
    2012 420 citations Allan Lipton, Karim Fizazi et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Veena Charu United States 18 770 605 494 284 262 45 1.7k
Oscar Ballester United States 15 1.3k 1.7× 780 1.3× 210 0.4× 320 1.1× 46 0.2× 42 1.9k
Stephen T. McSorley United Kingdom 22 1.3k 1.7× 95 0.2× 785 1.6× 98 0.3× 514 2.0× 79 2.1k
Sergio Storti Italy 20 419 0.5× 740 1.2× 94 0.2× 235 0.8× 74 0.3× 72 1.7k
Joseph M. Kiely United States 18 284 0.4× 158 0.3× 296 0.6× 99 0.3× 145 0.6× 39 1.3k
Gail Jones United Kingdom 18 224 0.3× 750 1.2× 53 0.1× 545 1.9× 54 0.2× 32 1.4k
Avi Leader Israel 20 365 0.5× 336 0.6× 135 0.3× 130 0.5× 36 0.1× 89 1.2k
Leslie R. Ellis United States 15 383 0.5× 432 0.7× 32 0.1× 318 1.1× 179 0.7× 48 1.5k
Noriko Hayami Japan 22 153 0.2× 118 0.2× 200 0.4× 355 1.3× 85 0.3× 134 1.5k
David J. Kuter United States 20 72 0.1× 926 1.5× 445 0.9× 211 0.7× 299 1.1× 50 1.8k
F. Yunus United States 8 622 0.8× 102 0.2× 319 0.6× 126 0.4× 157 0.6× 15 979

Countries citing papers authored by Veena Charu

Since Specialization
Citations

This map shows the geographic impact of Veena Charu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veena Charu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veena Charu more than expected).

Fields of papers citing papers by Veena Charu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veena Charu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veena Charu. The network helps show where Veena Charu may publish in the future.

Co-authorship network of co-authors of Veena Charu

This figure shows the co-authorship network connecting the top 25 collaborators of Veena Charu. A scholar is included among the top collaborators of Veena Charu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veena Charu. Veena Charu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Manda, Sudhir, Habte Yimer, Stephen J. Noga, et al.. (2020). Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clinical Lymphoma Myeloma & Leukemia. 20(11). e910–e925. 11 indexed citations
2.
3.
Berenson, James R., Ori Yellin, Chien-Shing Chen, et al.. (2014). A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Supportive Care in Cancer. 23(6). 1503–1512. 27 indexed citations
4.
Lipton, Allan, Karim Fizazi, Alison Stopeck, et al.. (2012). Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. 48(16). 3082–3092. 420 indexed citations breakdown →
5.
Mileshkin, Linda, Rodney J. Hicks, Brett Hughes, et al.. (2011). Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib. Clinical Cancer Research. 17(10). 3304–3315. 106 indexed citations
6.
7.
Gabrail, Nashat, Eric Sandler, Veena Charu, et al.. (2010). TROPICS 1: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters. Journal of Vascular and Interventional Radiology. 21(12). 1852–1858. 12 indexed citations
8.
Niesvizky, Rubén, Ian W. Flinn, Robert M. Rifkin, et al.. (2010). Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Results From the Phase 3b UPFRONT Study. Blood. 116(21). 3026–3026. 3 indexed citations
9.
10.
Glaspy, John A., Veena Charu, Donghan Luo, et al.. (2009). Initiation of epoetin‐α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy. Cancer. 115(5). 1121–1131. 7 indexed citations
11.
Schwartzberg, Lee S., Lorrin Yee, B. Mirtsching, et al.. (2007). A phase II, randomized, open-label study to assess the efficacy of extended-dose schedule administration of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. 5. 22–23. 1 indexed citations
12.
Henry, David H., Lucio Gordan, Veena Charu, et al.. (2006). Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Current Medical Research and Opinion. 22(7). 1403–1413. 21 indexed citations
13.
Senecal, Frank M., Lorrin Yee, Nashat Gabrail, et al.. (2005). Treatment of Chemotherapy-Induced Anemia in Breast Cancer: Results of a Randomized Controlled Trial of Darbepoetin Alfa 200 μg Every 2 Weeks Versus Epoetin Alfa 40,000 U Weekly. Clinical Breast Cancer. 6(5). 446–454. 20 indexed citations
14.
15.
Meza, Luís, et al.. (2005). Pegfilgrastim and filgrastim patterns of use in community oncology practices: Results of the ACCEPT study. Journal of Clinical Oncology. 23(16_suppl). 6113–6113. 3 indexed citations
16.
Schwartzberg, Lee S., Lorrin Yee, Frank M. Senecal, et al.. (2004). A Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia in Patients With Breast, Lung, or Gynecologic Cancer. The Oncologist. 9(6). 696–707. 80 indexed citations
17.
Charu, Veena, et al.. (2004). A controlled, randomized, open-label study to evaluate the effect of every-2-week darbepoetin alfa for anemia of cancer. Journal of Clinical Oncology. 22(14_suppl). 8084–8084. 2 indexed citations
18.
Schwartzberg, L., Lorrin Yee, Francis M. Senecal, et al.. (2004). Darbepoetin alfa (DA) 200 mcg every 2 weeks (Q2W) vs epoetin alfa (Epo) 40,000 U weekly (QW) in anemic patients (pts) receiving chemotherapy (ctx). Journal of Clinical Oncology. 22(14_suppl). 8063–8063. 2 indexed citations
19.
20.
Eisenberg, Peter D., Veena Charu, Julio Hajdenberg, et al.. (2003). Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist. Cancer. 98(11). 2473–2482. 327 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Oscar Ballester Breakdown of academic impact, for papers by Stephen T. McSorley Breakdown of academic impact, for papers by Sergio Storti Breakdown of academic impact, for papers by Joseph M. Kiely Breakdown of academic impact, for papers by Gail Jones Breakdown of academic impact, for papers by Avi Leader Breakdown of academic impact, for papers by Leslie R. Ellis Breakdown of academic impact, for papers by Noriko Hayami Breakdown of academic impact, for papers by David J. Kuter Breakdown of academic impact, for papers by F. Yunus
Rankless by CCL
2026